NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT03878095 2026-06-01Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting24 enrolled 12 charts